Altre lingue Sanofi

Azioni

SAN

FR0000120578

Prodotti farmaceutici

Tempo reale Euronext Paris Altri mercati azionari 16:44:21 10/03/2026			Variaz. 5gg	Var. 1 gen.
76,72 ^EUR	+1,20%		-3,94%	-7,27%

09/03	Le multinazionali del farmaco accelerano la presenza negli USA sotto la minaccia dei dazi	RE
09/03	Il farmaco di Pfizer contro l'eczema raggiunge l'obiettivo principale nello studio di fase intermedia; pianificato lo studio di fase avanzata	RE

Altre lingue

09/03	Global drugmakers rush to boost US presence as tariff threat looms
09/03	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study
08/03	Brazil’s EMS buys Medley
06/03	Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million
06/03	Brazil's EMS purchases Sanofi's Medley
05/03	Merck-Ausblick enttäuscht - Patentverlust bei MS-Mittel belastet
05/03	Sanofi : Depot AMF CP. D260030A01
05/03	Sanofi proposera à l'AG la nomination de Christel Heydemann comme administratrice
05/03	Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante
05/03	Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
05/03	Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee
05/03	Schwacher Dollar und Generika: Merck erwartet Gewinnrückgang
05/03	Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
04/03	Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel
04/03	Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
04/03	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
04/03	CAC 40 : La Bourse de Paris pourrait se stabiliser à l'ouverture, scrutant la situation au Moyen-Orient
04/03	Euroapi
04/03	Sanofi acquiert les droits exclusifs mondiaux d'un anticancéreux auprès de Sino Biopharmaceutical
04/03	Les valeurs à suivre à Paris et en Europe (actualisé)
04/03	Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals
04/03	Sino Biopharm Unit Signs Global License Deal With Sanofi for Rovadicitinib
04/03	Sino Biopharm Inks Up to $1.5 Billion Deal With Sanofi for Cancer Treatment
04/03	Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion
03/03	Blackstone Gives Teva $400 Million to Develop Inflammatory Bowel Disease Treatment